Remdesivir Medicine Market Will Hit Big Revenues In Future | Sanofi, Gilead Sciences, GlaxoSmithKline – Press Release

Remdesivir Medicine Market Will Hit Big Revenues In Future | Sanofi, Gilead Sciences, GlaxoSmithKline

Remdesivir Medicine Comprehensive Study by Application (Ebola Virus Disease, Marburg Virus Infection, Possible COVID-19 Treatment), Administration (Oral, Intravenous), End-users (Hospitals, Clinics, Ambulatory Surgical Centers, Others), Distribution Channel (Online Channel, Offline Channel) Players and Region – Global Market Outlook to 2025.

Global Remdesivir Medicine Market Comprehensive Study is an expert and top to bottom investigation on the momentum condition of the worldwide Global Remdesivir Medicine industry with an attention on the Global market. The report gives key insights available status of the Global Remdesivir Medicine producers and is an important wellspring of direction and course for organizations and people keen on the business. By and large, the report gives an inside and out understanding of 2020-2025 worldwide Remdesivir Medicine Market covering extremely significant parameters.

Key Players in This Report Include,
Gilead Sciences, Inc. (United States), Hainan Haiyao Co., Ltd. (China), Sanofi S.A. (France), GlaxoSmithKline plc (United Kingdom) and Cipla (India)

Free Sample Report + All Related Graphs & Charts @: https://www.advancemarketanalytics.com/sample-report/128698-global-remdesivir-medicine-market

Brief Summary of Global Remdesivir Medicine:
Remdesivir medicine is an anti-viral medication being studied as a possible post-infection treatment for COVID-19 illness. This medicine is a nucleotide analog, specifically an adenosine analog, which inserts into viral RNA chains causing their premature termination. It was developed by Gilead Sciences as a treatment for Ebola virus disease and Marburg virus infections. It is an investigational antiviral compound undergoing clinical trials in China, the United States and the United Kingdom as a potential treatment for COVID-19. It is not yet licensed or approved anywhere globally and has not been demonstrated to be safe or effective for any use.

Market Drivers

  • Increased Prevalence of COVID-19 Illness
  • Highly Effective Anti-viral Medicine

 

Market Trend

  • High Demand for Coronavirus Disease Treatment

 

Restraints

  • Lack of Clinical Evidence for COVID-19 Treatment

 

Opportunities

  • Increasing Number of Patients affecting COVID-19
  • Growth in the Healthcare Industry

 

Challenges

  • Stringent Government Rules and Regulations

This research report represents a 360-degree overview of the competitive landscape of the Global Remdesivir Medicine Market. Furthermore, it offers massive data relating to recent trends, technological, advancements, tools, and methodologies. The research report analyzes the Global Remdesivir Medicine Market in a detailed and concise manner for better insights into the businesses.

Regions Covered in the Global Remdesivir Medicine Market:

  • The Middle East and Africa (South Africa, Saudi Arabia, UAE, Israel, Egypt, etc.)
  • North America (United States, Mexico & Canada)
  • South America (Brazil, Venezuela, Argentina, Ecuador, Peru, Colombia, etc.)
  • Europe (Turkey, Spain, Turkey, Netherlands Denmark, Belgium, Switzerland, Germany, Russia UK, Italy, France, etc.)
  • Asia-Pacific (Taiwan, Hong Kong, Singapore, Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia).


Enquire for customization in Report @ https://www.advancemarketanalytics.com/enquiry-before-buy/128698-global-remdesivir-medicine-market

The research study has taken the help of graphical presentation techniques such as infographics, charts, tables, and pictures. It provides guidelines for both established players and new entrants in the Global Remdesivir Medicine Market.

The detailed elaboration of the Global Remdesivir Medicine Market has been provided by applying industry analysis techniques such

Read more

Pfizer Reports Lower Earnings As Covid-19 Hits Revenues

Pfizer reported lower third-quarter profits Tuesday as Covid-19 dented demand for some medicines from patients whose regular health care patterns were disrupted.

The drugmaker, which is working on clinical trials for a coronavirus vaccine, reported a 71 percent drop in profit to $2.2 billion. The year-ago period included a large gain connected to a transaction.

Revenues dipped four percent to $12.1 billion, missing analyst estimates.

Pfizer estimated a revenue hit of $500 million connected to Covid-19 due to lower pharma demand in China and fewer wellness visits from patients in the US.

Pfizer reported lower third-quarter profits, in part due to lower pharma demand as patients' normal patterns of healthcare were disrupted due to Covid-19 Pfizer reported lower third-quarter profits, in part due to lower pharma demand as patients’ normal patterns of healthcare were disrupted due to Covid-19 Photo: AFP / DOMINICK REUTER

The company saw an 11 percent drop in its hospital business in emerging markets, primarily due to fewer elective surgeries in China and shorter in-patient hospital stays in the country.

This effect was partially offset by increased demand for the Prevnar-13 vaccine for pneumonia “resulting from greater vaccine awareness for respiratory illnesses,” the company said.

Pfizer also cited strong performance in its biopharma business due to good sales for cancer drug Ibrance, anticoagulant Eliquis and other medications.

Pfizer said its Phase 3 Covid-19 trial had enrolled more than 40,000 participants, with nearly 36,000 having received their second vaccination as of Monday.

Shares rose 0.7 percent to $38,20 in pre-market trading.

Copyright AFP. All rights reserved.

Source Article

Read more